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CHAPTER 1: ROLES OF CHROMATIN-MODIFYING ENZYMES IN GENE 
REGULATION 
1.1 General Introduction 
 Epigenetic Regulation 
 
Nearly all cells of a multicellular organisms comprise the same DNA sequence and are 
genetically identical but are structurally and functionally diverse due to the variations observed in 
gene expression [1]. Besides a person's DNA sequence, there is an additional level of 
transcriptional control that decides which genes remain turned on and which remains turned off 
[2]. Epigenetic regulation involves the alteration of DNA and the proteins that are associated with 
DNA. This results in changes to the conformation of DNA and accessibility of other factors to 
DNA, without a change in actual DNA Sequence [2, 3]. Epigenetic regulation centers on chemical 
modifications that take place on DNA or specific amino acids in histone proteins that DNA is 
wrapped around. Three common forms of epigenetic regulation are 1) DNA methylation, 2) 
histone post- translational modifications and 3) RNA based mechanisms (micro-RNAs) (figure 
1.1) [3-5].  
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Figure 1.1: Summary of the three primary epigenetic mechanisms [6] 
(1) DNA methylation (2) Histone post translational modifications. (3) RNA-based 
mechanisms. 
DNA methylation is one of the epigenetic mechanisms used to regulate the gene expression 
which includes covalent transfer of methyl group catalyzed by DNA methyltransferases (DNMTs)  
to the cytosine ring of DNA molecule on C-5 position [7-10]. DNA methylation takes place in 
different biological processes, for instance, inactivation of X-chromosome, embryonic 
development, suppression of genes, chromosome stability, and carcinogenesis and plays an 
important part in maintenance of DNA stability and integrity [8, 11]. 
 Histone Post Translational Modification:  
DNA is wrapped around eight histone proteins into the structures known as 
nucleosomes.  Each nucleosome possesses copies of four core histones (H2A, H2B, H3, and H4) 
[12]. Histone tails undergo different post translational modifications catalyzed by different 
enzymes that recognize specific target sequences and alter the interaction of histones with DNA 
and nuclear proteins. This leads to epigenetic modifications for regulating several normal and 
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disease-related processes. Histone post-translational modification has its impact on gene 
expression and can also play an important role in diverse biological processes such as 
transcriptional activation and inactivation, chromosome packaging, and DNA damage/repair [12]. 
Methylation, phosphorylation, acetylation, ubiquitylation are the most common covalent post-
translational modification (PTM) to histone proteins  [13-15]. 
 
Figure 1.2: Most common post translational modifications to histone proteins [16] 
 Histone Methylation  
It is the process that involves addition of methyl groups to the histone proteins mediated 
by histone methyltransferases (HMTs). This epigenetic modification mainly occurs on histone tails 
to the lysine and arginine residues which leads to gene activation or repression based on the amino 
acid residue that is methylated. Arginine residues may be mono- or di- methylated whereas, lysine 
residues may be methylated once, twice or thrice. There are several different histone 
methyltransferases known to methylate specific arginine or lysine residues. Depending upon where 
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the methyl groups are transferred by the HMTs, the name changes. So, if the methyl group is 
transferred to the lysine residue they are known as lysine methyl transferases (HKMT) and if it is 
transferred to an arginine residue they are known as arginine methyl transferases (HRMT) [17, 
18]. 
 Histone Ubiquitylation  
It is an enzymatic post-translational modification that involves addition of a ubiquitin 
molecule to a substrate protein most commonly to the lysine residue of a substrate [19]. Ubiquitin 
is an 8-kDa polypeptide found in eukaryotic cells. It is present either in free state or is found 
covalently linked to other proteins [20]. This is a conserved eukaryotic protein that is attached to 
histone lysine via successive action of three enzymes, E1- UB activating enzyme, E2- UB 
conjugating enzyme and E3- UB ligase [20, 21]. Both, the substrate specificity (i.e., where lysine 
is targeted) and the degree of ubiquitylation (i.e., either mono- or poly-ubiquitylated) is regulated 
by the enzyme complexes. Histone H2A and H2B are two most highly ubiquitylated proteins found 
in the nucleus. Histone ubiquitylation plays a central role in the DNA damage response and in 
many other cellular processes, including transcriptional regulation, protein degradation along with 
protein-protein interactions. My research focus on the structure and function of ubiquitin-
conjugating enzyme as well as lysine methyltransferases in human and yeast.  
 Histone Lysine Methyltransferases: 
Histone lysine methyltransferases (HKMT) is a part of Histone methyltransferases (HMT) 
that catalyze the transfer of methyl groups from the co-factor SAM (S-adenosylmethionine, 
AdoMet). AdoMet comprises of methylthiol group which is highly reactive. This methyl group 
is then added to the ε-amino group of a lysine residues on histones H3 and H4 [22, 23] forming 
mono-, di-, or tri- methylated products in addition to its analogue adenosylhomocysteine 
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(AdoHcy). Once the methyl marks are added to the lysine residue, it can result in regulation of 
protein function by either recruiting binding proteins or direct effects. [24]. Lysine 
methyltransferases (KMT) can be classified into SET domain-containing and non-SET domain-
containing proteins. SET domain is a highly conserved catalytic unit and found the in majority of 
known KMTs. Several non-SET-domain KMTs have also been identified e.g. DOT1L, METTL10 
etc. SET-domain containing proteins have become more important in epigenetics and have been 
linked to cancer. They are involved in numerous diseases and play a crucial role in regulating gene 
transcription. Although, the functions of histone methyltransferases have been explored, the  
pathological mechanisms and downstream of lysine methylation remain to be elucidated [24]. 
 SMYD Proteins 
SMYD protein family is an important class of lysine methyltransferases which catalyzes 
methylation reaction on both histones and non-histone targets [25]. At present, five members of 
SMYD family including SMYD1, SMYD2, SMYD3, SMYD4 and SMYD5 have been identified 
which plays diverse biological functions and are involved in epigenetic transcription regulation, 
cancer proliferation and the immune system [26]. Two highly conserved structural and functional 
domains, the SET and MYND domains is present in all the members of the SMYD protein family. 
This conserved domain plays a role in lysine methylation and protein-protein interaction, 
respectively. SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) domain in N-lysine 
methyltransferases is approximately 130 aa long and is a highly conserved catalytic motif 
responsible for methyltransferase activity by adding methyl marks to lysine residues of proteins 
using SAM as a methyl group donor [27]. SET domain is “split” by MYND (Myeloid-Nervy-
DEAF1) domain. It is a cysteine-rich zinc finger motif and is mainly involved in protein-protein 
interaction with preference for binding with a proline rich motif (PXLXP). It is well-defined by a 
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single histidine residue and a seven conserved cysteine residues that are arranged in a C4- C2HC 
consensus sequence [26]. In addition to this, another feature is CTD (C- terminal domain) known 
as tetratricopeptide repeats (TPR) domain, a motif important in the binding of co-chaperones such 
as HSP90 is found in SMYD1-4 and is absent in SMYD5 which makes it different from other 
SMYD proteins [26]. Whereas, SMYD4 contains additional TPR domain at its N-terminus. SMYD 
protein family is known to methylate a variety of histone and non-histone proteins that contribute 
to a myriad of biological processes. Smyd5, a 47kD protein is identified as an H4 Lys20 
methyltransferase and contains a polyglutamate insertion in its C-terminal domain. Our laboratory 
demonstrated that SMYD5 is localized in the nucleus which translocate from the nucleus to 
cytoplasm upon hydrogen peroxide treatment. Biological roles of SMYD5 have started to emerge 
in the area of immune reaction, embryonic stem cell regulation, hematopoiesis regulation, DNA 
double stranded break repair as well as cancer inhibition but at the same time, the physiological 
and biochemical function of SMYD5 remains largely unknown [25]. Therefore, it would be 
interesting to determine its role and function and gain further mechanistic insights.  
 KMTs in Budding Yeast:  
Proteins undergo one of the major post-translational modification known as methylation. 
So far, KMTs methylating histone proteins contain the catalytic SET domain required for their 
enzymatic activity [28] whereas, only one histone KMT, Dot1, possesses a seven-β stranded 
domain in Eukaryotes [29]. Lysine 79 methylation of H3 occurs in eukaryotes ranging from 
budding yeast to human. K79 methylation in budding yeast is mediated by silencing protein DOT1 
and H3 -K79 methylation is conserved from Yeast to human [28]. Budding yeast contains about 
12 members of KMTs containing SET domain family, while the human proteome contains more 
than 50 KMTs [29]. Six methyltransferases involved in various biological processes were 
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examined in budding yeast namely, Rkm4, Rkm1, Efm7 and Efm4 which are known to methylate 
specific lysine or N-terminal residues of different subunits of translational machinery [30, 31]. 
Hmt1 is known to regulate post transcriptional processes [32]. SET5 which is the identified as first 
histone methyltransferase monomethylating the H4 at three lysine residues in the context of stress 
response [29]. It methylate’s H4 tail at lysine 5, 8 and 12 in budding yeast [29]. SET5 and SET6, 
contains the split SET domain and two consecutive Zinc finger motifs. These structural features 
as well as the sequence comparison designates that SET5 is orthologous to human SMYD3 protein. 
SMYD3 is also known to methylate H4K5 which specifies functional conservation of the activity 
of SET5. The study of H4 methylation and SET5 in budding yeast may thus reveal conserved 
mechanisms that add to SMYD3-dependent oncogenesis and the evolutionary mechanism of 
chromatin function in human can also be known [29]. Until the present, HMT1 is the only methyl 
transferase in yeast whose biological structure has been solved [33]. So, our goal is to solve and 
study the structure and function of SET5 in budding yeast in order to understand the mechanism 
of methylation.               
 Ubiquitin Conjugating Enzyme:  
One of the small regulatory proteins present in all eukaryotic cells is ubiquitin. It is a highly 
conserved protein and can exist either free or be covalently linked to other cellular or nuclear 
proteins [34, 35]. Ubiquitin conjugates with the intracellular proteins and marks their selective 
degradation. This process is known as ubiquitination [35]. Proteins are affected in many ways by 
ubiquitination. It can mark them for proteasomal degradation, alter their activity, change their 
cellular location etc. The three main steps in ubiquitination process are; Initially, the ubiquitin 
activating enzyme (E1) activates the ubiquitin molecule by binding to it. This activated ubiquitin 
molecule is then transferred to the ubiquitin conjugating enzymes (E2) which covalently attaches 
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the ubiquitin moiety to the target protein with or without the help of an E3 enzyme known as the 
ligase enzyme [36]. The protein is mark for proteasomal degradation when either single or more 
ubiquitin molecule is attached to it [37]. Therefore, the fate of the substrate i.e. signaling or 
proteasomal degradation is finally determined by ubiquitin conjugating enzyme (E2) [38]. A 
protein which catalyzes the covalent attachment of ubiquitin molecule to the specific proteins is 
encoded by a Rad6 gene [37, 38]. Rad6 protein which is highly conserved eukaryotic protein [39] 
plays an important role in various cellular processes including post-replication repair, damage-
induced mutagenesis, sporulation, and DNA recombination [40]. It also plays a key role in 
proteasomal degradation pathway and cell signaling [38, 41, 42].The post-translational 
modification of targeted proteins via ubiquitin regulates the RAD6B pathway, which obligates 
them to rapid proteolysis [38, 40, 42]. This demonstrated that Rad6 protein is an essential 
ubiquitin-conjugating enzyme [37, 43] that plays an important role in maintenance of genetic 
integrity of mammalian cells. Imbalance in the levels of RAD6B protein could lead to 
chromosomal instability, aneuploidy, transformation and hypersensitivity towards drugs [42]. 
RAD6B is weakly expressed in normal human breast tissues but its expression rises in breast 
cancer cells [44]. Therefore, maintaining the critical level of RAD6B is very important [42]. 
Targeted treatment strategies using small molecule inhibitors are extensively studied [45]. SMI#9 
is a selective small molecule inhibitor of RAD6B. My major goal is to solve the crystal structure 
of Rad6B in complex with SMI9 or its derivatives. Solving the structure of Rad6B/SMI9 complex 
will provide an excellent basis for rational design of more potent, selective Rad6B inhibitors. 
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CHAPTER 2: EXPRESSION, PURIFICATION, CRYSTALLIZATION AND ACTIVITY 
STUDIES OF HISTONE LYSINE METHYLTRANSFERASE: SMYD5 
2.1 Introduction 
 SMYD protein family containing conserved SET and MYND domains plays a crucial role 
in myofibril assembly and is known to involved in muscle and heart development. This class of 
protein lysine methyl transferases has also been known to possess roles in tumorigenesis. So far, 
SMYD family consists of five paralogues. The catalytically active SET domain is responsible for 
cofactor binding, and methylation of lysine residues on histone and non-histone targets. The 
MYND domain is a zinc finger motif that plays a key role in protein-protein interaction. 
 
Figure 2.1: Overall structure of SET and MYND domain- containing protein family 
(SMYD) [46] 
The diagram represents the structural domain organization of five members of SMYD 
protein family. The MYND, SET and TPR domains are highlighted yellow, green and blue 
respectively. Poly-E region of SMYD5 is highlighted brown. The numbers represent the 
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numbering of amino acids of each domain (numbers on top of each region) and overall size 
(numbers at the end) of the human proteins. 
Research indicated that the structural and physiological roles played by the other SMYD 
members are distinct from that played by SMYD5. SMYD5 lacks TPR domain, important for the 
modulation of protein-protein interactions, and is present in other members of SMYD family. 
Instead SMYD5 has a poly-glutamate stretch. Unlike other members of SMYD family, SMYD5 
does not have a function in the development of cardiac and skeletal muscle. SMYD5 was found to 
play a role in hematopoiesis in zebrafish. SMYD5 is associated with the NCoR co-repressor 
complex and was found to repress the expression of toll-like receptor 4 (TLR4) responsive genes 
in macrophages. It was also found to regulate pro-inflammation genes through trimethylation of 
H4K20. Embryonic stem (ES) cells self-renewal is directed by networks of epigenetic regulators 
and transcription factors. Disruption of these factors abolishes self-renewal. Recent studies 
indicated that, SMYD5 is an important regulator of ES cell function. SMYD5 is highly expressed 
in ES cells and its depletion resulted in compromised self-renewal. Deregulation of SMYD 
proteins has been informed to contribute to cancer progression through several different 
mechanisms. Research has indicated a possible role of SMYD5 in breast cancer through epigenetic 
alterations, most likely playing a role as tumor suppressor. 
 SMYD5, which is identified as H4K20 methyltransferase, may also play a larger role by 
methylating substrates other than histones. As stated earlier, the physiological function of SMYD5 
is not well understood. Therefore, to understand its function better, one way is to identify its new 
substrates which will help us understand how SMYD5 recognizes its substrates. 
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 Lysine Oriented Peptide Libraries (KOPLs) for Determination of KMT Substrate 
Selectivity: 
Based on the substrate selectivity profile, our laboratory designed an artificial substrate 
peptide for SMYD5, known as KOPL peptide. The name of the peptide is based on the technique 
used to design it which is, “Lysine oriented peptide libraries”. The peptide is 7 aa long, whose 
sequence is KAVKSYK. The substrate peptide screening for SMYD5 was done by our 
collaborators. 
 
Figure 2.2: Screening result for KOPL peptide 
In figure 2.2, 6 different positions (P-3 – P+3) were tested and in each position, the Z 
position is fixed which is one of the 20 amino acids. Xs are the degenerate amino acids which may 
vary from among the 20 amino acids. K (lysine) is always kept same. Accordingly, 20 amino acids 
will be tested for each position. The residue most preferred for each position was determined.  
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Figure 2.3: Schematic determination for determination of activity for each peptide with 
different sequences 
Activity is performed in a 96 well plate, in which, the coated streptavidin binds to the biotinylated 
peptides, SAM is radiolabeled, KMT is SMYD5, me is the methyl group containing tritium group 
transferred from SAM (denoted in red); Light emission is measured to determine the 
methyltransferase activity. 
In figure 2.2, radiolabeled SAM was used to detect the methyltransferase activity. Here, 
the activity was tested on each peptide at each position with different sequence. Once, the methyl 
group is transferred from SAM to the lysine residue by the methyltransferase, the amount of light 
emission is measured to determine the methyltransferase activity. The SMYD5 substrate 
selectivity profile can then be determined by the composite methylation score. Based on this, we 
designed the best substrate for SMYD5. 
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Figure 2.4: Composite score of each peptide with different sequences 
Figure 2.4 is a heat map that represents the composite score for each position (P-3 – P+3). 
Some amino acids are better, and others are worse. In the left of the figure are all types of amino 
acids except for cysteine. To the top of the figure, are the 6 positions, and to the right of the figure, 
is the color scale which tells that, red means highly preferred residues and blue represents low 
preferred residues. From the map, we can say that, for the P-3 position K is the most preferred 
residue, For P-2 position M is the most preferred one. For P-1 V is the most preferred residue, K0 
is target lysine, which is kept constant. S, Y and K are the preferred residues for P+1, P+2, and 
P+3 positions respectively. This is how we designed the KOPL peptide for SMYD5 whose 
sequence is KAVKSYK. Based on the substrate selectivity profile, the KOPL peptide is assumed 
to be the best peptide for SMYD5 and may facilitate its crystallization. 
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2.2 Materials and Methods 
 Protein Expression and Purification 
 The open reading frame of full length human SMYD5 was cloned into pCDF-SUMO 
vector with N-terminal His6-SUMO tag and transformed into the host BL21 (DE3) cells for 
recombinant protein expression. 
 
 
 
Figure 2.5: pCDF-SUMO Vector Map 
 Small Scale Expression Test 
Small scale expression test is used to check whether the protein is soluble and expressed 
well. The conditions can be optimized accordingly. The transformants were grown in 5mL LB 
media to an optical density of 0.4-0.6 at 37ºC at 600nm. The culture was then induced with 0.1 
mM IPTG and grown overnight at 15ºC. Cells were harvested next day and lysed by sonication. 
Induced and uninduced samples were collected to test expression, and cell lysate and supernatant 
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samples were collected to determine protein solubility. The results were analyzed on 15% SDS-
PAGE. 
 Large Scale Expression 
Large scale expression is used to express and produce the protein of interest for protein 
purification. The volume of cells to grow will depend upon (1) how well the protein is expressed, 
which can be analyzed from the small-scale expression test described above and (2) how much 
protein we want to have. The gene encoding for wild type SMYD5 protein was cloned into pCDF- 
SUMO vector and transformed into BL21(DE3) cells. Transformants were grown to an OD600 of 
0.4-0.6 at 37º C in LB medium and protein expression was induced with 0.1mM IPTG 
(isopropylthio-β-D-galactoside). The cell growth was continued at 15ºC with shaking of 225 rpm 
overnight. Cells were harvested by centrifugation and suspended in binding buffer (20 mM sodium 
phosphate, 500 mM NaCl, 5% glycerol, 20 mM imidazole, 5 mM BME). Cells were lysed by 
French Press and the supernatant containing the soluble proteins was subjected to protein 
purification by three step chromatography using AKTA purification system including two times 
of Ni2+ affinity followed by size exclusion. The recombinant wild type SMYD5 contains a His6-
SUMO-tag which was bound to HisTrap coloumn (GE Healthcare). The bound protein containing 
the His6 tag was eluted out by elution buffer (20 mM sodium phosphate, 500 mM NaCl, 5% 
glycerol, 500 mM imidazole, 5 mM BME). Fractions containing His6-SUMO-SMYD5 were 
pooled together. The SUMO tag bound to the protein  was cleaved off by adding Ulp1 (SUMO 
protease 1). The native SMYD5 protein was collected by passing the protein through the second 
Ni2+ affinity chromatography column (HisTrap). Finally, SMYD5 was further purified through a 
Superdex 200 column (GE Healthcare) into gel filtration buffer (20 mM Tris pH 7.5, 150 mM 
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NaCl, 5% glycerol, 5 mM BME). Fractions containing pure wild type SMYD5 protein were pooled 
and concentrated and stored at -80ºC for further use. 
 
 
 
 
Figure 2.6: Overview of the purification strategy of SUMO-SMYD5 using AKTA system 
[47] 
 Methyltransferase Activity Assay 
 Methyltransferase assay is used to monitor the activity of a methyltransferase enzyme on 
its substrates. Here, we used a continuous kinetic assay to detect the methyltransferase activity of 
SMYD5. It is a robust assay for the continuous monitoring of methyltransferase activity and can 
be used to determine the steady-state kinetics (e.g., kcat and KM) for a variety of 
methyltransferases.  
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Figure 2.7: Continuous coupled assay for determination of methyltransferase activity [48] 
Assay utilizes three enzymes: SAH nucleosidase (SAHN), Adenine deaminase (ADE) and 
Glutamate Dehydrogenase to couple methyl transferase activity to NADPH oxidation. SAM is 
used as methyl group donor. Activity was carried out in standard cuvette and monitored by a 
decrease in absorbance at 340nm. 
In this assay, MTs activity is coupled to three different enzymes namely; adenine 
deaminase (ADE), SAH nucleosidase (SAHN) and glutamate dehydrogenase to couple 
methyltransferase activity to NADPH oxidation. As a result, the rate of NADPH oxidation reflects 
the rate of methylation and the methyltransferase activity can directly be monitored by a decrease 
in absorbance at 340 nm. The activities of SAHN and ADE are coupled with the activity of 
glutamate dehydrogenase that utilizes ammonia and alpha-ketoglutarate to generate glutamate 
followed by NADPH oxidation. The continuous change in absorbance at 340 nm due to NADPH 
oxidation is examined, which can be linearly correlated with the reduced concentration of SAM. 
Before the readings were documented, all the assay reactions were incubated at room temperature 
for 20 mins with the final volume of 60µl. 
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Figure 2.8: The chemical structure of all the products in methyl transferase coupled assay 
[48] 
SAM is converted to SAH by methyltransferase enzyme. With the help of SAH 
nucleosidase, SAH is converted to Adenine + S-Ribosylhomocysteine. Adenine is then converted 
to hypoxanthine + α-ketoglutarate + NADPH by Adenine deaminase. α-ketoglutarate is then 
converted to glutamate and NADPH is oxidized to NAD(P)+ by Glutamate Dehydrogenase. 
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 DOT Blot Assay 
 A dot blot is a method used to detect peptides and proteins. It can also be adapted to 
determine the methyl transferase activity by detecting methylated products. It signifies a 
simplification of the western blot method, with that the proteins or peptides to be detected are not 
first separated by electrophoresis. Instead, the samples are applied directly on a membrane in a 
single spot, and the blotting procedure is performed. 
 
Figure 2.9: Overview of DOT Blot assay technique 
Reaction was set up in 1.6 mL microcentrifuge tube at 30ºC overnight. The reaction 
contains 5µg KOPL+2mg/ml SMYD5+2mMSAM. Next day, 3 drops, 2µl of each, were plotted 
on nitrocellulose membrane. Blocking was carried out with 5% BSA for 1 hour at room 
temperature. Next, washing of membrane was carried out with TBST buffer for 3 times, 8 mins of 
each. Then, membrane was incubated with primary antibody (1:1000) for 1 hour at room 
temperature. Then, membrane was washed two times for 8 mins to remove any traces of primary 
antibody. Then the membrane was incubated with secondary antibody (1: 10000) for 50 mins 
followed by TBST wash of 3 times. Then, the secondary antibody labelled with HRP conjugate 
can be detected by ECL exposure. 
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  Protein Crystallization of SMYD5 
 MBP-SMYD5(purified by one of the laboratory members) was used to set up the crystal 
screens. The buffer exchange was performed prior to crystallization, and SMYD5 was transferred 
into a bicine buffer (50mM bicine pH 9.0, 50mM NaCl, 0.5mM DTT). Protein concentration was 
diluted to 10 mg/mL. Various crystal screens such as, Crystal Screen 1 and Index Screen (Hampton 
Research) were used to perform crystallization. Crystal screens were also set up by incubating 10 
mg/mL MBP-SMYD5 protein and 1 mM concentration of SAM for 1 hour on ice. Both hanging 
drop and sitting drop vapor diffusion techniques were used to set up crystal screens, by the addition 
of 1 ul of the well solution to 1 ul of protein sample. These crystallization trials were performed at 
21°C.  
2.3 Results 
 SMYD5 Crystallization Attempts 
 Full length SMYD5 gene was successfully cloned into pCDF-SUMO vector in the BL21 
cells and was used for the future experiments. SMYD5 protein was expressed and purified by 
AKTA purification system by three step chromatography. About 1.25 mg of SMYD5 protein was 
purified from 4L of E.Coli cells. 
 Crystallization trials using MBP-SMYD5 were conducted with different sparse matrix 
crystal screens, were conducted at 21ºC. The sitting drop and hanging drop vapor diffusion 
techniques were used. Conditions appeared mostly heavily (Figure 2.12) or lightly precipitated 
(figure 2.10). Only 1 or 2 conditions showed phase separation (figure 2.11). However, no 
promising conditions were obtained. 
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.              
Figure 2.10: Light precipitated condition 
0.2M sodium citrate tribasic dihydrate,0.1M sodium cacodylate trihydrate pH 6.5, 30% 
v/v 2-propanol  
 
Figure 2.11: Phase separation condition 
0.2M Ammonium sulfate, 0.1M sodium cacodylate trihydrate PH 6.5, w/v PEG 8000  
 
 
Figure 2.12: Heavy precipitated condition  
0.2M Calcium chloride dehydrate, 0.1M HEPES sodium pH 7.5, 28% v/v PEG 400  
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 SMYD5 Methylate’s KOPL Peptide in Kinetic Assay 
 Kinetic assay was performed with a full length human SMYD5 in bicine buffer, pH 9.0. 
When all the assay components were present, a gradual change in absorbance at 340 nm was 
observed. This assay was used to measure the methyl transferase activity of SMYD5 on KOPL 
peptide with SAM as a methyl group donor. Two control reactions were run: (1) 500 µM NADPH, 
4.5 µM SAHN, 3 µM ADE and Glutamate 2.62U (Figure 2.13) and (2) 300 µM KOPL peptide, 
300 µM SAM, 4.5 µM SAHN, 3 µM ADE, Glutamate 2.62U (Figure 2.13). These control reactions 
ensured that the change in absorbance at 340 nm reflected the true measurement of methylation 
activity of SMYD5 on KOPL peptide. No activities were detected for the control reactions. 
 When the reaction was run, which contained 5 µM of full length SMYD5, 300 µM KOPL 
peptide, 300 µM SAM, 4.5 µM SAHN, 3 µM ADE and Glutamate 2.62U (Figure 2.13), a 
significant change in the absorbance at 340 nm was detected indicating the methyltransferase 
activity of full length SMYD5 protein on KOPL peptide by using SAM as a methyl group donor. 
As a result, the methyltransferase activity was directly monitored by the decrease in the absorbance 
at 340 nm. 
 
Figure 2.13: Methyltransferase activity monitored at 340nm 
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Blue line (KOPL+SAMNADPH+ coupled enzymes) and orange line (NADPH+ coupled 
enzymes) indicates the control reactions do not detect any activity. Grey line 
(SMYD5+KOPL+coupled enzymes) indicates the methyltransferase activity of SMYD5 on KOPL 
peptide by the change in the absorbance at 340 nm. 
  SMYD5 methylate’s KOPL peptide in Dot Blot 
 
Figure 2.14: Dot Blot shows that SMYD5 methylate’s KOPL peptide 
H4 is a known substrate for SMYD2 and was used as a positive control in the Dot Blot 
assay. SMYD2+H4+SAM reaction gave positive signal. No signal was detected for SMYD3+H3 
because, no SAM was added. It was used as a negative control in the reaction. For SMYD5, a little 
activity was detected with the H4K20 peptide, which is the known substrate of SMYD5; whereas, 
KOPL+SMYD5+SAM reaction gave a strong positive signal which suggested that SMYD5 could 
potentially methylate KOPL peptide.  
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2.4 Discussion 
Our results from kinetic coupled assay and Dot Blot assay detected the methyltransferase 
activity of full length SMYD5 on KOPL peptide. These results were consistent with one another 
and suggested that, full length SMYD5 can methylate KOPL peptide, which is a synthetic artificial 
SMYD5 substrate designed by our laboratory. SMYD5 showed very little activity on H4K20 
peptide, which is a known substrate for SMYD5. 
In this study, multiple approaches were used to obtain the crystals. MBP-SMYD5 protein 
was used to perform crystallization trials. Crystallization conditions with different sparse matrix 
screens were performed. Yet, the trials yielded no crystals. One of the possible reasons may be due 
to the fusion tag. The fusion tags are known to increase the solubility of target protein and are 
being used for protein crystallization techniques to facilitate crystal lattice formation. However, 
despite increasing the chances of crystallization, the tagged proteins may have conformational 
heterogeneity due to the linker region and might not form crystals. 
Crystallization conditions are specific to each protein. In future, crystallization experiments 
will be performed using full length SMYD5 in complex with KOPL peptide. Our results indicated 
that, full length SMYD5 can methylate KOPL peptide which may enhance the chances of 
crystallization. Second approach will be to perform re-cloning by designing new constructs that 
will exclude the flexible C-terminal region which might enhance the protein rigidity and facilitate 
crystallization of SMYD5. 
  In summary, this study provided evidence that KOPL peptide, which is designed based on 
SMYD5 substrate selectivity profile, could be the best substrate for SMYD5 protein. Alternative 
approaches like radioactive assays that involve the use of tritium (3H) labeled SAM to study the 
methyltransferase activity can be used to further confirm that KOPL might be the first non-histone 
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substrate of SMYD5. In addition, this peptide can be used in co-crystallization experiments with 
full length SMYD5 that may facilitate its crystallization. 
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CHAPTER 3: TO SOLVE THE CRYSTAL STRUCTURE OF THE HISTONE KMTS 
SET5 FROM BUDDING YEAST (SACCHAROMYCES CEREVISIAE) 
3.1 Introduction 
 Methylation of lysine residues is performed by lysine methyltransferases. SET5 is the first 
histone H4 lysine methyltransferase found in budding yeast that can add methyl marks to the lysine 
residues on histone H4. It is known to monomethylate the important H4 lysine residues 5, 8 and 
12 in yeast.   
 
Figure 3.1: SET5 methylates lysines 5,8 and 12 [49] 
It is also known that SET can methylate a native H4 in bulk purified histones and full length 
recombinant H4. It is also known to methylate lysine residues 4 and 7 on H2A to a minor extent. 
SET5 contains a split SET domain and has 2 consecutive Zn fingers. These structural elements 
and sequence comparisons specify that SET5 is orthologous to human SMYD3 methyltransferase, 
which likewise contains the split SET domain and zinc finger MYND domain. The study of SET5 
and H4 methylation in yeast may therefore uncover conserved mechanisms that contribute to 
SMYD3 dependent oncogenesis in human cells. 
 Histone methyl marks indicate appropriate programming of the genome and have been 
associated in the advancement of several human diseases. Recent study suggested that SET5 might 
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interact with the chromatin to monomethylate histone H4 in cells. Yeast knockout assay for SET5 
indicated that, loss of SET5 alone does not significantly affect global transcription. Genetic 
interaction studies suggested that SET5 functions with two global chromatin-modifying complexes 
namely; the COMPASS complex and NuA4 complex. COMPASS complex contains the H3K4 
methyltransferase Set1 and the NuA4 complex contains the H4K5, H4K8 and H4K12 
acetyltransferase Esa1. This data revealed that, H4 methylation and acetylation function in the 
same pathways [29]. 
The telomeres in budding yeast have been served as a model for studying the function of 
varied chromatin proteins in regulating and organizing chromatin structure and gene expression 
for many years. Expression of genes close to the telomeres in budding yeast are transcriptionally 
repressed by a combined set of chromatins modifying and remodeling elements. Apart from 
histone acetylation, histone H3 methylation also plays a role in silencing of adjacent genes to the 
telomeres. Previously, it was thought that silencing of genes adjacent to the telomeres was mainly 
mediated by the complex of Sir protein, but recent studies revealed the combined role of SET1 
which is an H3K4 methyltransferase and SET5 which is known to methylate H4K5, H4K8 and 
H4K12 promotes a Sir protein-independent mechanism of telomere silencing [50]. Results stated 
a novel functional correlation amongst H3 and H4 methyltransferases, whose collective activities 
may possibly be associated in maintaining genomic integrity [51]. 
Additional biochemical and structural studies are required to reveal the mechanisms 
directing SET5 substrate selectivity and specificity and to understand the regulatory control of its 
enzymatic activity. 
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 Protein Crystallization 
 The study of biochemical mechanisms and intermolecular interactions of a protein 
molecule can be performed by solving its macromolecular structure. This can be done either by 
nuclear magnetic resonance (NMR) or by using X-ray crystallography. NMR technique can only 
be used with low molecular weight proteins. X-ray crystallography is a technique used for 
determining the atomic and molecular structure of a protein which can be of higher molecular 
weight. X-ray diffraction patterns can be obtained from protein crystals. Getting a protein crystal 
is a difficult and an energetically unfavorable process. Achieving protein supersaturation is 
required for crystal formation, which requires manipulation of crystallization conditions such as 
pH, temperature, salt concentration, reducing agent, organic molecules etc. 
In this method a protein crystal is exposed to an X-ray beam, resulting in a diffraction 
pattern collected on an X-ray detector. Then, by analyzing the angles and intensities of these 
diffracted beams, we can obtain an electron density map.  From this electron density map the mean 
positions of the atoms of the protein can be modeled and determined, which finally leads to the 3D 
structure of the protein. (Figure 3.2) 
 
Figure 3.2: Overview of X-ray Crystallographic Method [52] 
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Out of all the methods known to crystallize a protein, the most commonly used technique 
is the vapor diffusion technique. Vapor diffusion takes place in a closed system, where the protein 
is mixed with the reservoir solution in 1:1 volume in a drop. A slow gradient of increasing protein 
concentration takes place as the solution evaporates from the drop and finally ends up into the 
reservoir to achieve the equilibrium. The two most common techniques used for vapor diffusion 
are sitting drop and hanging drop vapor diffusion techniques (figure 3.3) which shares the same 
principle.  
 
Figure 3.3: X-ray crystallographic methods [47] 
Left represents sitting drop vapor diffusion technique. Right represents hanging drop vapor 
diffusion technique. 
Once the promising conditions are obtained, they will be optimized further in order to get 
larger crystals and achieve better X-ray diffraction. Careful observation of the results of 
crystallization experiments is necessary to determine the parameters that are optimal for 
crystallization. 
3.2  Materials and Methods 
 Crystallization  
 Sequence alignment of SET5 with the other members of the SMYD family revealed that 
SET5 is an orthologue of human SMYD3. However, obtaining crystal structure of SET5 will 
reveal how SET5 recognizes its substrates and how it is associated with human SMYD protein. 
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 Purified His-SET5 was collected from our collaborators. Crystallization attempts were 
performed with the protein to identify conditions yielding diffraction quality crystals. The protein 
was diluted to 5mg/mL concentration. Sinefungin (SFG) was added in 1:10 volume of protein and 
cofactor. The protein and cofactor together were incubated at 4ºC for ~ 2 hrs. The protein mix was 
centrifuged at 11800 rpm for 10 mins to get rid of any aggregates that might prevent the formation 
of crystals. Sitting drop vapor diffusion technique was used to test different reservoir solutions to 
determine which conditions facilitate crystallization. Commercially available sparse matrix 
crystallization screens such as Crystal Screen Ⅰ and Index Screen (Hampton Research) were used. 
Crystal screens were set up by addition of 1 µl of the well solution to 1 µl of protein mix and 
incubated at 22° C. The screens were monitored for optimized conditions.  
3.3 Results 
 
Figure 3.4: Set5 crystals 
With the protein concentration of 5 mg/mL and crystal condition of 0.2 M ammonium 
acetate, 0.1 M Tris-HCL pH 8.5, 15% 2- propanol, a few crystals appeared within 2 weeks and 
continued to grow to its maximum size the following week. His-SET5 crystals were harvested and 
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flash frozen in liquid nitrogen. Crystals were sent to APS (Advance Photon Source) for X-ray 
diffraction data collection.  
X-ray diffraction data from crystals will be collected at the Advanced Photon Source (APS) 
using LS-CAT X-ray synchrotron. Wayne State is a standing member of APS LS-CAT and has 
guaranteed access to synchrotron beam lines. APS offers the brightest X-ray beam that allows us 
to determine X-ray structures to the highest possible resolution as well as the ability to work with 
difficult samples. Once the data is collected, the structure can be solved by the molecular 
replacement method. 
3.4 Discussion: 
 In this study we were able to find out the conditions that can obtain of SET5 crystals.  A 
few crystals were obtained by the sitting drop vapor diffusion technique by mixing 5 mg/mL 
protein with the equal volume of reservoir solution containing 0.2 M Ammonium acetate, 0.1 M 
Tris-HCL pH 8.5, 15% 2- propanol.  
 In summary, this study provided the starting condition for optimization of SET5 crystals. 
This condition could potentially lead to obtaining well diffracted SET5 crystals. Attaining high 
resolution structures of SET5 would be of value since SET5 is a known orthologue of human 
SMYD3 protein. SMYD3 has been implicated in tumorigenesis. Hence, further studies on SET5 
may uncover conserved mechanisms that contribute to SMYD3 oncogenesis in human cells. 
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CHAPTER 4: STRUCTURE BASED OPTIMIZATION OF THE INHIBITORS OF 
RAD6B, A POTENTIAL DRUG TARGET FOR BREAST CANCER TREATMENT 
4.1 Introduction 
Cancer is one of the most serious health threats and leading causes of death [53]. Breast 
cancer is an invasive cancer which generally affects women. It is the second main leading cause 
of deaths [54]. One in every 8 women will develop breast cancer in her lifetime. Many mutations 
occur as a result of problems caused by DNA lesions during replication [55]. This process termed 
as mutagenesis is a major pathogenic factor because the mutations are thought to inactivate cellular 
defenses against uncontrolled proliferation and cell migration which is a common factor in cancer. 
There is currently no cure for metastatic breast cancer, and this poses the need for strong cancer 
research which will enhance our understanding about cancer and help us to develop novel and 
more effective treatment techniques. Traditional therapies have been proved powerful in the 
treatment of cancer but one of its disadvantages is that it leads to adverse side effects due to its 
toxicity on both tumorous as well as normal cells [56, 57]. Targeted treatment strategies using 
small molecule inhibitors are being widely studied [58]. Small molecule inhibitors (SMI) are the 
compounds ≤ 500 Da in size. They can reach the intracellular target sites by diffusing across the 
plasma membrane due to their small size. These compounds can disrupt protein-protein 
interactions and can be used in cancer treatment [58]. 
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Figure 4.1: Cancer death statistics [53] 
 Rad6 gene encodes a highly conserved eukaryotic protein, RAD6B, that plays a role in the 
covalent attachment of ubiquitin to the other targeted proteins. RAD6B protein is an important E2 
conjugate that mediates ubiquitination reaction. This protein plays a key role in various cellular 
processes such as post-replication DNA repair, recombination and damage induced mutagenesis. 
 One of the substrates for RAD6B is histone H2A protein. Ubiquitination of histone H2A 
is one of the post translational modification in DNA damage response. Ubiquitination reaction 
involves three main steps: activation, conjugation, and ligation, performed by three different 
enzymes namely, ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), 
and ubiquitin ligases (E3), respectively. 
 
Figure 4.2: Overview of ubiquitination reaction mediated by RAD6B 
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Ubiquitin molecule is activated by ubiquitin-activating enzyme (E1) which is ATP 
dependent step. Next, ubiquitin-conjugating enzymes (E2) catalyzes the transfer of ubiquitin from 
E1 to the active site of the E2. Ubiquitin ligases (E3), catalyzes the final step of the ubiquitination 
cascade. This reaction may lead to mono, multi or poly ubiquitination at the substrate molecule 
which finally leads to DNA repair. 
Normal human breast tissues weakly express Rad6B protein but its expression increases in 
breast cancer tissues [44]. Thus, deregulation in expression of RAD6B may be an important step 
in transformation to the malignant phenotype [42, 44]. β catenin or other components of Wnt 
pathway are activated in most breast cancers. An increase in the level of β catenin, states its crucial 
role in breast cancer[58]. Rad6B which is overexpressed in breast cancerous cells plays a 
remarkable role in β catenin ubiquitination and stabilization [59]. Therefore, maintaining the 
critical level of RAD6B is very important. 
Aiming at Rad6B would be a promising way for breast cancer treatment. Proteasome 
inhibitors which are inaccessible to provide specificity will be achieved by small molecule 
inhibitors (SMI) which are selective for Rad6B [60]. The human Rad6B protein has been 
crystallized previously [61]. With the help of molecular docking, the novel SMIs #8 and #9 that 
interfere with Rad6B catalytic sites have also been identified [60]. SMI#9 more effectively induced 
apoptosis, cell cycle arrest in G2-M phase and inhibited proliferation, migration and colony 
formation and Rad6B induced histone ubiquitination. SMI#9 is also known to decline β catenin 
levels [60].  
The crystal structure of Rad6B in complex with SMI#9 is not available. This has prevented 
a rational design of inhibitors with better selectivity and potency. Solving the crystal structure of 
Rad6B/SMI#9 complex will provide us with more accurate binding information of the key residues 
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of Rad6B which interacts with its small molecule inhibitor SMI#9. This will provide us with the 
information of the best binding poses of SMI#9 with Rad6B. Based upon the structural findings, 
the compound can be optimized in terms of electrostatic interactions, the fit in ligand binding 
pocket, and van der Waals contacts. This data is expected to create new Rad6B inhibitors with 
enhanced potency and selectivity. The generated compounds will be drug-like, synthesizable and 
can be used to inhibit the overexpression of Rad6B in breast cancer and hence can be applicable 
in breast cancer treatment. 
4.2 Materials and Methods 
 Molecular Cloning and Protein Expression 
RAD6B gene was initially present in PET101 vector which was collected from our 
collaborators. The gene of interest needs to be amplified from genomic or vector DNA by PCR 
(polymerase chain reaction) before it can be cloned into an expression vector. The first step is to 
design the necessary primers. 
5’ primer was designed which was 35 bp in length, 
TTATATGGTCTCAAGGTATGTCGACCCCGGCCCGG (Tm=68ºC) and included the 
Bsa1(GGTCTC) restriction enzyme site. 3’ primer was 33bp in length, 
GCCGCGCTCGAGTTATGAATCATTCCAGCTTTG (Tm=65.1ºC) and included a Xho1 
restriction site. The primers were ordered from Invitrogen company. 
 DNA fragment amplification encoding full length Rad6B was performed by PCR and then 
cloned into the pCDF-SUMO vector. RAD6B gene was amplified by PCR and then analyzed on a 
0.8% agarose gel (Figure: 4.3). This was followed by the purification of PCR products using the 
PCR cleaning kit (Qiagen company) and then performing double digestion using Xho1 and Bsa1 
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restriction enzymes. Vector and insert digested by the restriction enzymes were purified and 
extracted using gel extraction kit (Qiagen company). 
Purified insert and vector were mixed together with quick DNA ligase enzyme to 
circularized into a vector DNA and then followed by transforming the vector DNA into DH5α 
cells for plasmid expression. Plasmid purification was performed using GenEluteTM Plasmid 
Miniprep kit (Sigma), and then plasmid samples were sent for DNA sequencing to GENEWIZ. 
 Transformation for Protein Expression 
 1 µL of miniprep product containing the vector DNA was transformed into the 50 µL of 
codon optimized BL21 cells and heat shocked for 45 seconds at 42˚C. 250 µL of prewarmed SOC 
medium was added to the BL21 cells and incubated for 1 hour with 225 rpm of shaking at 37 ˚C 
and then plated onto streptomycin LB agar plates to get the recombinant colonies. Glycerol stocks 
were made with the overnight 5mL culture made from a single recombinant colony. 1 mL BL21 
cell culture+300μL of 80% glycerol was mixed together in 2mL coring tubes, labeled and stored 
at -80˚C for future use. 
 Small Scale Expression Test 
 For recombinant protein expression, BL21 codon plus cells containing RAD6B gene were 
grown at 37ºC to an optical density of 0.4 – 0.6 and protein expression was induced with 0.1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were grown overnight at 15ºC with 225 rpm 
of shaking. Next day, the OD600 was measured, and cells were lysed using sonicator. Lysate and 
supernatant were collected to compare for the solubility test of a protein. The results were analyzed 
on 15% SDS PAGE. (Figure 4.4) 
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 Large Scale Protein Production by Induction with IPTG 
 5mL LB media +1X streptomycin was inoculated with the BL21 cells containing RAD6B 
gene in pCDF-SUMO plasmid. Overnight culture was added to 500mL prewarmed LB medium 
containing streptomycin antibiotic for recombinant RAD6B protein production and purification. 
The sample of overnight culture was saved for SDS-PAGE analysis. The 500 mL inoculated 
culture was grown at 37 for 2 – 3 hours until the OD600 was between 0.4 – 0.6. The culture was 
slowly cooled down to 15ºC and induced with 0.1mM IPTG and grown overnight. The induced 
sample was saved for SDS-PAGE analysis. (Figure 4.5) 
 Protein Purification by AKTA System 
Rad6B was purified by three-step chromatography including two times of Ni2+ affinity 
followed by size exclusion. The cells grown by IPTG induction were harvested by centrifugation 
and lysed by French Press. The soluble fraction was then subjected to Ni2+ affinity 
chromatography purification. The His-SUMO tag was removed by SUMO protease1 to produce 
native RAD6B. RAD6B proteins were separated from the cleaved tag by a second Ni2+ affinity 
chromatography and further purified by size-exclusion chromatography. Finally, the proteins were 
concentrated to 10–20 mg/mL in a buffer containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 
mM β-mercaptoethanol, 5% glycerol, and 5 mM BME. Fractions containing pure RAD6B were 
pooled, concentrated to 35.4 mg/mL and stored in the -80°C for future use. (Figure 4.6-4.10) 
 Western Blotting 
Purified RAD6B protein with three different concentrations (0.5µg, 1µg, 2 µg) were loaded 
onto 15% SDS-PAGE for electrophoresis and then transferred onto a nitrocellulose membrane. 
Next, membrane blocking was performed using nonfat dry milk for 1 hour at room temperature 
followed by 5 minutes of 1X TBST wash for 3 times. Immunoblotting was performed by 
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incubating the primary antibody (1:3000) against RAD6B, overnight at 4°C. The membrane was 
then washed 3 times for 5 mins using 0.1% TBST and the secondary antibody (1:5000; Goat anti-
mouse IgG(H+L) HRP, Invitrogen) was incubated for 1 hour at room temperature. ECL (HyGLO 
HRP detection kit) was then used to detect the signal. The blots were developed using X-ray film 
where the light is emitted from the chemical reaction between secondary antibody, which is 
conjugated to HRP and the ECL solution used to detect the signal.  
 Activity Assay 
Activity assay was carried out where, 1 µg of RAD6B protein bought from Boston 
Biochem laboratory was used as a control and three different concentrations, 1 µg, 2 µg and 4 µg 
of purified RAD6B in our laboratory were used to test the activity. All the proteins were incubated 
with histone H2A (1 µg), ubiquitin (0.5 µg), ATP/Mg+2 and E1 enzyme in 10x UBC buffer for 1 
hour at 30ºC. The reaction was stopped by boiling with SDS buffer containing BME and analyzed 
by western blot, same as described before. 
 Crystallization 
Crystallization was performed using the hanging drop vapor diffusion method with the 
purified RAD6B. Various crystal screens were set up with and without SMI#9. The crystals were 
obtained by mixing the equal volume of reservoir solution containing 0.1M bisTris, pH 7.5,0.1M 
sodium tartrate, 1.3 M ammonium sulphate, 10% DMSO and RAD6B protein (10mg/ml) at 20ºC. 
Crystals appeared in one day and continued to grow for next 2 to 3 days. Crystals were stained 
with 0.1% of methylene blue to confirm if the crystals obtained were protein crystals and not salt 
crystals. The crystal appeared blue after staining indicating protein crystals. 
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4.3 Results 
 
Figure 4.3: PCR result 
RAD6B gene inserted in pCDF-SUMO vector was amplified by PCR and analyzed on 
0.8% agarose gel. The 1st and the 2nd lane represent the 100bp and 1 kb DNA markers. Lanes 3rd, 
4th and 5th represents the band corresponding to the molecular weight of RAD6B gene which was 
amplified by PCR with 3 different concentrations of MgCl2, 4 mM, 8 mM and 6 mM respectively. 
 RAD6B Construct Cloning and Purification  
The RAD6B gene was transformed into BL21 cells for protein expression and purification. 
Small scale expression test was performed to check the solubility and expression level of 
recombinant RAD6B. 
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Figure 4.4: Small scale expression test 
In the figure (4.4), RAD6B protein containing the SUMO tag is indicated with the 
corresponding band of expected molecular weight. The 1st lane represents protein marker. 2nd and 
3rd lane represents uninduced and induced samples. 4th and 5th lane represents lysate and 
supernatant samples. 
RAD6B protein purification was performed using AKTA purification system. In large 
scale purification process, the RAD6B expression and solubility tests were further confirmed by 
running 15% SDS PAGE. The cell lysate containing the SUMO tagged RAD6B protein was loaded 
onto the 1st HisTrap column.  
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Figure 4.5: Large scale expression test 
1st, 2nd and 3rd lanes represent the wash, flow through and sample loaded onto the column. 
4th, 5th, 6th and 7th lanes represent the supernatant, lysate from French pressed cells, induced and 
uninduced samples from large scale expression. The last lane is the protein molecular weight 
marker. SUMO-RAD6B band corresponding to its molecular weight is indicated. 
According to the chromatogram of 1st HisTrap purification (Figure 4.6), A6-B2 protein 
fractions were analyzed by 15% SDS-PAGE (Figure 4.7), indicating that A8 to B1 contained most 
of the RAD6B proteins. These fractions were then pooled together and incubated with SUMO 
protease overnight to cut the SUMO tag from RAD6B, followed by desalting (Figure 4.8). 
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Figure 4.6: 1st HisTrap chromatogram 
 
 
Figure 4.7: 1st HisTrap Fractions 
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Figure 4.8: Loading protein to the desalting 
Protein marker, before cut (B. Cut), after cut (A. Cut), desalting load, desalting flowthrough 
(FT), desalting pool, before concentration (B.conc), and concentrated flowthrough (Conc. FT), 
were analyzed by 15% SDS PAGE. 
An aliquot of the samples from each step was saved and examined by running 15% SDS-
PAGE (Figure 4.8). After running the samples on 2nd HisTrap column, SUMO tag was bound to 
the column and Rad6B was collected, concentrated and loaded onto Superdex 200 column. The 
fractions from the 2nd peak (figure 4.9) were collected and analyzed on 15% SDS-PAGE (Figure 
4.10) in which C3- C7 fractions were pooled together, filtered and concentrated. Finally, 12 mg 
(35.4 mg/mL, 250μl) RAD6B protein was obtained from 2 liters of E.coli cell culture. 
 
Figure 4.9: S200 chromatogram 
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Figure 4.10: S200 fractions 
 Western Blotting 
 To confirm whether the purified protein was a RAD6B protein, western blot analysis was 
performed. Three different concentrations of the protein which was purified in our laboratory using 
AKTA purification system were analyzed. The results indicated that the protein was recognized 
by anti- RAD6B antibody and exhibited a band corresponding to the expected molecular weight 
(17 kDa) of RAD6B. This indicated that the purified protein was indeed a RAD6B protein. 
 
 
Figure 4.11: Western Blot analysis to detect the presence of RAD6B protein 
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The 1st lane is the molecular weight marker followed by three different concentrations 
(0.5µg, 1 µg, 2 µg) of purified Rad6B. The bands were seen at the molecular weight of 17kDa in 
all three concentrations. 
 Activity Assay 
Activity assay was performed using anti-ubiquitin antibody to detect the ubiquitination 
reaction carried out by RAD6B protein on H2A. Here, we used three different concentrations of 
RAD6B protein purified in our laboratory (1 µg, 2 µg and 4 µg) to test the activity. 1 µg of the 
protein bought from Boston Biochem laboratory was used as a control. In Figure 4.12, bands 
corresponding to 10 kD and 17 kD marker were observed in all the four concentrations of protein 
indicating ubiquitin monomer and ubiquitin dimer respectively. In 2 µg and 1 µg (control) protein 
concentration only a single upper band was detected corresponding to 28 kD marker which 
suggested that it was a RAD6B protein containing a ubiquitin molecule. However, in the 4 µg 
protein concentration, two bands (upper and lower) around 28 kD marker were observed. The two 
bands were close to each other and suggested that the upper band was RAD6B with ubiquitin 
molecule attached to it while the lower band was H2A, to which the ubiquitin molecule was 
attached. This suggested that the Rad6B protein was in the process of transferring the ubiquitin 
molecule to its substrate H2A. This activity was observed clearly in 4 µg concentration of the 
protein and very little in 1 µg (control) concentration.  
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Figure 4.12:Ubiquitin conjugating activity of RAD6B 
1 µg, 2 µg and 4 µg concentrations are the RAD6B proteins purified in our laboratory. The 
second 1 µg concentration is the protein bought from Boston Biochem laboratory. 
 Crystallization 
Crystal screens were set up with purified RAD6B protein to obtain crystals. After 
introducing different concentrations of SMI#9 with different crystallization conditions. Crystals 
appeared the next day with 1.3M ammonium sulfate,0.1M bis-Tris pH 7.5,0.1M sodium tartrate, 
and 10 % DMSO. The crystals grew bigger the next day. The crystals appeared blue after addition 
of 0.1% of methylene blue which suggested the crystals were protein crystals. These crystals will 
be optimized to achieve adequate diffraction quality for data collection.  
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Figure 4.13: Crystals obtained for RAD6B protein. 
Crystals obtained by hanging drop vapor diffusion technique using10mg/mL of protein. 
Crystals appeared overnight and continued to grow. 
4.4 Discussion: 
 In this study, RAD6B gene was successfully cloned into pCDF-SUMO vector and a 
significant amount of proteins was purified using E. coli as a production host. We performed the 
western blot analysis of the purified protein using anti-RAD6B antibody. The results indicated that 
the protein we purified was indeed a RAD6B protein. Next, we performed an activity assay to 
detect the ubiquitin conjugating activity of the purified RAD6B protein on its substrate H2A. The 
results indicated that the RAD6B protein we purified was able to carry out ubiquitination reaction 
on H2A. This indicated that the purified protein was active. We were also able to obtain the crystals 
of RAD6B, which serves as a good starting point for structure determination. These crystals will 
further be optimized to grow bigger crystals, suitable for X-ray diffraction and data collection.  
 Further studies to solve the crystal structure of RAD6B/SMI9 complex will provide the 
excellent basis for a rational design of more potent and selective small molecule inhibitors. New 
RAD6B inhibitors with improved potency and selectivity can be designed by using a combined 
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ligand and receptor-based method. In summary, our study has paved the way for developing novel, 
small and selective molecule inhibitors of RAD6B which can be used to treat breast cancer in 
future.  
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 X-ray crystallography is a powerful tool in the elucidation of the three-dimensional 
structure of bio molecules such as proteins and nucleic acids. Obtaining their structures will allow 
deep understanding of their biochemical mechanisms and how the alterations in the structures 
influence human health. X-crystallography has been used as an important approach to understand 
the structural and biochemical properties of histone modifying enzymes and shed light on poorly 
understood mechanisms. 
 SMYD5, one of the members of SMYD protein family, is identified as a histone lysine 
methyltransferase. Lysine methylation is known to modulate various biological processes 
including DNA damage response and gene regulation. SMYD5 is involved in hematopoiesis 
regulation, immune response and tumorigenesis. So far, the biochemical and structural features 
required to understand its methyl transferase function remains elusive. Solving the crystal structure 
and identifying the new substrates of SMYD5 will provide a molecular window to visualize how 
these biological molecules influence human health. In this study, we conducted the crystallization 
attempts and various biochemical assays to understand the function of SMYD5. To identify if 
SMYD5 can methylate non histone substrates, an artificial peptide, assumed to be the best peptide 
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substrate for SMYD5 was designed based on the substrate selectivity profile of SMYD5. We found 
that SMYD5 is much more active on this peptide than its known histone substrate H4K20 in both 
enzyme kinetics assay and dot blot assay.  
Methylation controls chromatin regulation which is catalyzed by SET domain-containing 
methyltransferases. SET5 was identified as the first histone methyltransferase enzyme in budding 
yeast. It is known to monomethylate the important H4 lysine residues, H4K5, H4K8 and H4K12. 
Studies have been demonstrated a functional relationship between histone H3 and histone H4 
methyltransferases, whose combined activities play roles in preserving genomic integrity. Also, 
SET5 is recognized as human SMYD3 ortholog, which also catalyzes the methylation at H4K5. 
Therefore, SET5 functional studies might reveal previously unknown conserved mechanisms that 
may contribute to SMYD3 dependent oncogenesis in human cells. In this study, X-ray 
crystallographic studies were utilized to solve the crystal structure of SET5. Our initial 
crystallization screening has successfully resulted in Set5 crystallization. Solving its crystal 
structure will shed light on poorly understood mechanisms of SET5-mediated histone H4 
methylation. 
Rad6B plays a key role in breast cancer cell growth. It is a ubiquitin conjugating enzyme 
(E2) which mediates ubiquitination. It is essential for the post-replication, DNA repair and 
genomic integrity maintenance via its ubiquitin-conjugating activity. Alterations in ubiquitination 
occur frequently in cancer. Because Rad6B is overexpressed in breast cancer cells, targeting 
Rad6B would be a viable approach for breast cancer treatment. SMI9 is a specific small molecule 
inhibitor of Rad6B. It is known to inhibit Rad6B-induced histone H2A ubiquitination, induce G2–
M arrest and apoptosis, downregulate intracellular β-catenin and inhibit proliferation and 
migration of metastatic human breast cancer cells. In our study, the crystals were obtained for 
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Rad6B which will serve as a good starting point to and solve macromolecular structure of Rad6B 
in complex with SMI9. Solving the crystal structure will facilitate the development of new Rad6B 
inhibitors which can be used to inhibit the overexpression of Rad6B in breast cancer. 
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